申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:US20140031277A1
公开(公告)日:2014-01-30
The present invention relates to compounds of formula I:
or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS
3
-NS
4
A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
本发明涉及以下式I的化合物:或其药学上可接受的盐或混合物,其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒NS3-NS4A蛋白酶的活性。因此,它们通过干扰丙型肝炎病毒的生命周期发挥作用,并且还可用作抗病毒剂。本发明还涉及包含这些化合物的组合物,无论是用于体外使用还是用于治疗患有HCV感染的患者的给药,并涉及制备这些化合物的过程。本发明还涉及通过给予本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。